Larimar Therapeutics Inc. (LRMR)
Larimar Therapeutics Statistics
Share Statistics
Larimar Therapeutics has 64.03M shares outstanding. The number of shares has increased by 0.35% in one year.
| Shares Outstanding | 64.03M |
| Shares Change (YoY) | 0.35% |
| Shares Change (QoQ) | 0.35% |
| Owned by Institutions (%) | 99.41% |
| Shares Floating | 36.68M |
| Failed to Deliver (FTD) Shares | 1.15K |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 5.63M, so 8.8% of the outstanding shares have been sold short.
| Short Interest | 5.63M |
| Short % of Shares Out | 8.8% |
| Short % of Float | 15.92% |
| Short Ratio (days to cover) | 6.52 |
Valuation Ratios
The PE ratio is -2.94 and the forward PE ratio is -1.3. Larimar Therapeutics's PEG ratio is -0.05.
| PE Ratio | -2.94 |
| Forward PE | -1.3 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 1.38 |
| P/FCF Ratio | -3.33 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Larimar Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.02, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.02 |
| Quick Ratio | 8.02 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.07 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.24M |
| Employee Count | 65 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -62.55% in the last 52 weeks. The beta is 0.93, so Larimar Therapeutics's price volatility has been higher than the market average.
| Beta | 0.93 |
| 52-Week Price Change | -62.55% |
| 50-Day Moving Average | 2.44 |
| 200-Day Moving Average | 5.42 |
| Relative Strength Index (RSI) | 67.61 |
| Average Volume (20 Days) | 858.32K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -90.89M |
| Net Income | -80.6M |
| EBITDA | -90.89M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.32 |
Balance Sheet
The company has 33.22M in cash and 5.12M in debt, giving a net cash position of 28.1M.
| Cash & Cash Equivalents | 33.22M |
| Total Debt | 5.12M |
| Net Cash | 28.1M |
| Retained Earnings | -269.16M |
| Total Assets | 200.22M |
| Working Capital | 170.95M |
Cash Flow
In the last 12 months, operating cash flow was -70.76M and capital expenditures -515K, giving a free cash flow of -71.28M.
| Operating Cash Flow | -70.76M |
| Capital Expenditures | -515K |
| Free Cash Flow | -71.28M |
| FCF Per Share | -1.16 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LRMR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LRMR is $18, which is 531.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 531.6% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on May 29, 2020. It was a backward split with a ratio of 1:12.
| Last Split Date | May 29, 2020 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | 0.81 |
| Piotroski F-Score | 1 |